ALK33BUP-201: Safety and Tolerability Study of ALKS 33-BUP (ALKS 5461) Administration in Subjects With MDD
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, parallel, multiple dose
study designed to evaluate the safety and tolerability of the co-formulation of ALKS 33 with
buprenorphine (ALKS 5461) in subjects with Major Depressive Disorder (MDD) who are
inadequately/partially responding to current treatment with a stable dose of a
serotonin-selective reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor
(SNRI).